Investing.comDoubao · 实盘不做把握 3/10不做原因:无增量信息
北京时间·🕒 发布 05:04:31·⟳ 抓取 05:05:20 +49s·⚡ 决策 10-12 05:07:54 +2m34s·15.6 天前
Mirum 宣布将于周一电话会公布 LIVMARLI 三期 EXPAND 研究顶线结果，结果尚未披露
这是一次临床数据读出的『预告』而非数据本身：EXPAND 三期顶线（成败、疗效幅度、安全性）要到周一 8:30 ET 才公布，多空完全取决于尚未披露的二元结果；此刻为美股周日闭市、无法成交，凭预告抢跑等于在二元事件前赌博，不具可研究的正向 edge，故 AVOID，待顶线数据落地后再据结果研判。
📄 原文Investing.com↗ 原文
Mirum Pharmaceuticals to share phase 3 LIVMARLI study results
By Investing.com Advertisement Advertisement Mirum Pharmaceuticals to share phase 3 LIVMARLI study results Company News…
不做 Mirum Pharmaceuticals, Inc.（MIRM.US）
仅为周一三期 EXPAND 顶线数据读出的会议预告，疗效/安全性结果完全未知，方向取决于二元临床结局；此刻美股周日闭市无法成交，事前抢跑无法用止损覆盖隔夜跳空，无正期望。等周一顶线公布（主要终点是否达成、胆道闭锁标签扩展量级）并观察开盘承接后再决定做多或做空。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Mirum 仅预告周一公布 LIVMARLI 三期 EXPAND（胆道闭锁瘙痒）顶线结果，没有任何数据，属典型未兑现的二元临床催化剂；结果未知且市场闭市，方向不成立，等数据出来再交易。
🔎 新鲜度:最早出现 2026-10-11 · 扩散 low · price-in 风险 medium ↗
关键理由
- 无方向性做多依据：会议预告不含疗效信号，胆道闭锁标签扩展能否成立要等周一顶线数据。
- 事件本质是 event-driver 的二元押注而非已确认利好，结果双向（成功扩张标签/失败重估），不构成可提前布局的正期望。
主要风险
- 周一电话会可能在盘前公布，MIRM 大概率大幅跳空，数据好/坏均可能产生 20%+ 隔夜缺口，事前头寸无法用常规止损控制。
- 小盘罕见病股单品种集中度高，市场可能已对 EXPAND 成功隐含较高预期，即便达标也可能见光死。
反向证据
- 做多前查反向 · 来源 web · 影响 weakens
当前信号不含结果，无法证实成功；EXPAND 成败为二元未知，构不成可核验的多头事实，反向（失败）同样无法排除。
检索:Mirum MIRM EXPAND phase 3 biliary atresia topline failure risk maralixibat 原文 ↗
先例如何影响了这次决策
对本次决策的影响:直接导致 AVOID：不在未知二元结果前建仓，待周一顶线公布后再据成败、量级与开盘承接决定方向。
方向:无可用对齐先例：本条为读出前预告而非数据事件，历史小盘罕见病股三期读出应以『顶线实际公布日』为锚，而非会议预告日，故不以预告锚定任何涨幅。
涨幅量级:不足以校准幅度；三期标签扩展数据读出的跳空幅度高度依赖主要终点 p 值与安全性，属二元结果，不应在结果前设定 tp/sl。
形态:小盘生物股数据读出常见盘前大幅跳空且成败两极分化，事前抢跑胜率无统计优势；这支持等待数据而非提前布局。
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 16 ms
{"result": "search_processed_events:agent query=`mirm expand biliary atresia cholestatic pruritus phase 3 data | mirum pharmaceuticals livmarli maralixibat phase 3 expand topline results investor call`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或
原文全文
展开原文 · 6,812 字
Mirum Pharmaceuticals to share phase 3 LIVMARLI study results By Investing.com
Advertisement
Advertisement
Mirum Pharmaceuticals to share phase 3 LIVMARLI study results
Company News
Published
Oct 11, 2026, 05:04 PM
Mirum Pharmaceuticals to share phase 3 LIVMARLI study results
View all comments (0)
0
Mirum Pharmaceuticals to share phase 3 LIVMARLI study results
View all comments (0)
0
© Reuters
In this article:
MIRM
+
5.73%
FOSTER CITY, Calif. -
Mirum Pharmaceuticals
, Inc. (
NASDAQ:MIRM
) will host an investor call on Monday at 8:30 a.m. ET to present topline results from its Phase 3 EXPAND study, according to a press release statement.
The study evaluates LIVMARLI (maralixibat) for treating cholestatic pruritus in patients aged 6 months or older with ultra-rare cholestatic liver diseases, including biliary atresia.
The conference call can be accessed by dialing +1 833 461 5787 for U.S. callers or +1 585 542 9983 for international participants, using access code 486697901. A webcast will be available on the Investors section of the company’s website, with an archived replay available afterward.
LIVMARLI is currently approved for Alagille syndrome and progressive familial intrahepatic cholestasis. The company’s commercial portfolio also includes ATEBRIOZ for fibrodysplasia ossificans progressiva, CHOLBAM for bile-acid synthesis disorders, and CTEXLI for cerebrotendinous xanthomatosis.
Mirum’s clinical-stage pipeline includes volixibat for primary sclerosing cholangitis and primary biliary cholangitis, brelovitug for chronic hepatitis delta virus, and MRM-3379 for Fragile X syndrome.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Mirum Pharmaceuticals to share phase 3 LIVMARLI study results
View all comments (0)
0
Latest comments
Post
Comment Guidelines
Trade With A Regulated Broker
Indices
Commodities
Bonds
Stocks
US 30
51,703.90
+472.2
+0.92%
US 500
7,816.30
+50.8
+0.65%
Dow Jones
51,654.95
+423.31
+0.83%
S&P 500
7,811.54
+46.18
+0.59%
Nasdaq
27,366.17
+172.83
+0.64%
S&P 500 VIX
14.84
-0.57
-3.70%
Dollar Index
102.03
+0.010
+0.01%
Crude Oil WTI Futures
91.66
+0.17
+0.19%
Brent Oil Futures
104.42
-0.30
-0.29%
Natural Gas Futures
3.20
+0.040
+1.14%
Gold Futures
4,220.30
+63.30
+1.52%
Silver Futures
61.11
+1.690
+2.84%
Copper Futures
6.71
+0.1400
+2.17%
US Soybeans Futures
1,292.25
+4.75
+0.37%
U.S. 10Y
5.244
+0.011
+0.21%
U.S. 30Y
5.599
-0.008
-0.14%
U.S. 5Y
5.021
+0.030
+0.60%
U.S. 3M
4.159
+0.008
+0.19%
US 10Y T-Note Futures
104.59
-0.13
-0.12%
Euro Bund Futures
121.08
+0.41
+0.34%
10-2 Yield Spread
31.32
+4.15
+15.27%
AAPL
336.64
-3.78
-1.11%
NVDA
229.28
-1.20
-0.52%
GOOGL
351.66
+3.37
+0.97%
TSLA
382.70
+7.70
+2.05%
AMZN
262.43
+8.37
+3.29%
NFLX
70.30
-1.27
-1.77%
META
718.67
-2.22
-0.31%
Advertisement
Most Popular Articles
News
Analysis
8 emerging markets to consider in 2027: HSBC
By Investing.co
...
Oct 11, 2026
Iran rejects U.S. stance on Hormuz as Trump weighs strikes over Riyadh attacks
By Investing.co
...
Oct 11, 2026
Will rising French bond spreads disrupt the rally in European stocks?
By Investing.co
...
Oct 10, 2026
Investors are likely to focus on SpaceX’s Starship tech milestones, not results
By Investing.co
...
Oct 12, 2026
Russia and Ukraine agree to energy ceasefire amid U.S. threat to cut military aid
By Investing.co
...
Oct 11, 2026
Beyond Chips: The 3 Layers of the AI Value Chain
By Ivana Delevs
...
Oct 10, 2026
OpenAI’s $20B Revenue Gap: Warning Signs for US Stocks?
By Lee Yang
Oct 09, 2026
Treasury Auctions Explained: Why Bond Auctions Matter Even If You Dont Trade Bonds
By Matthew Well
...
Oct 10, 2026
Sequence of Return Risk: The Math That Breaks Retirements
By Lance Robert
...
Oct 10, 2026
Gambling Epidemic: Gen Z Betting Against Their Future?
By Lance Robert
...
Oct 09, 2026
More News
Market Movers
Most Active
Gainers %
Losers %
Name
Last
Chg. %
Vol.
MU
1,029.00
-0.66%
19.92M
NVDA
229.28
-0.52%
84.65M
SPCX
162.57
+1.25%
93.04M
TSLA
382.70
+2.05%
38.95M
AAPL
336.64
-1.11%
37.88M
MSFT
535.07
+2.38%
18.50M
AMZN
262.43
+3.29%
34.77M
Name
Last
Chg. %
Vol.
CCI
79.64
+15.60%
14.39M
MRNA
225.00
+14.21%
28.95M
HUM
431.87
+11.56%
4.99M
AMT
182.24
+9.30%
8.51M
SBAC
182.49
+7.34%
2.36M
DDOG
293.26
+7.11%
3.71M
AKAM
106.95
+6.00%
5.80M
Name
Last
Chg. %
Vol.
TMUS
148.58
-13.27%
19.03M
T
22.18
-10.82%
150.53M
VZ
41.65
-10.14%
95.17M
HPQ
30.20
-6.91%
16.70M
FMC
8.35
-6.39%
5.19M
CHTR
103.38
-5.74%
5.11M
FICO
667.58
-5.63%
1.09M
Advertisement
Trending Stocks
Name
Last
Chg. %
Vol.
PLTR
209.05
+5.17%
37.62M
NVDA
229.28
-0.52%
84.65M
SPCX
162.57
+1.25%
93.04M
MRNA
225.00
+14.21%
28.95M
MU
1,029.00
-0.66%
19.92M
Show more
Advertisement
ProPicks AI
AI-powered
stock picks
with a proven track record to
beat the S&P 500
.
Tech Titans
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Top Value Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best of Buffett
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Energy Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Financial Fortresses
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Quality Compounders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Small-Cap Sprinters
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Healthcare Heroes
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Beat the S&P 500
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Dominate the Dow
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mid-Cap Movers
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mexican Stock Exchange Leaders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best Brazilian Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Italian Market Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Alpha Germany Select
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Comments
Post
Comment Guidelines
Tools
Calendars
Economic Calendar
Earnings Calendar
Holiday Calendar
US Economy
Fed Rate Monitor Tool
US Treasury Yield Curve
More Tools
Stock Screener
Currency Converter
Markets
Ask WarrenAI
Stocks Picked by AI
Watchlist
Alerts
Top Brokers
Breaking News
Tools
Install Our App
Scan QR code to install app
Follow us
Advertisement
Advertisement
Mirum Pharmaceuticals to share phase 3 LIVMARLI study results
Company News
Published
Oct 11, 2026, 05:04 PM
Mirum Pharmaceuticals to share phase 3 LIVMARLI study results
View all comments (0)
0
Mirum Pharmaceuticals to share phase 3 LIVMARLI study results
View all comments (0)
0
© Reuters
In this article:
MIRM
+
5.73%
FOSTER CITY, Calif. -
Mirum Pharmaceuticals
, Inc. (
NASDAQ:MIRM
) will host an investor call on Monday at 8:30 a.m. ET to present topline results from its Phase 3 EXPAND study, according to a press release statement.
The study evaluates LIVMARLI (maralixibat) for treating cholestatic pruritus in patients aged 6 months or older with ultra-rare cholestatic liver diseases, including biliary atresia.
The conference call can be accessed by dialing +1 833 461 5787 for U.S. callers or +1 585 542 9983 for international participants, using access code 486697901. A webcast will be available on the Investors section of the company’s website, with an archived replay available afterward.
LIVMARLI is currently approved for Alagille syndrome and progressive familial intrahepatic cholestasis. The company’s commercial portfolio also includes ATEBRIOZ for fibrodysplasia ossificans progressiva, CHOLBAM for bile-acid synthesis disorders, and CTEXLI for cerebrotendinous xanthomatosis.
Mirum’s clinical-stage pipeline includes volixibat for primary sclerosing cholangitis and primary biliary cholangitis, brelovitug for chronic hepatitis delta virus, and MRM-3379 for Fragile X syndrome.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Mirum Pharmaceuticals to share phase 3 LIVMARLI study results
View all comments (0)
0
Latest comments
Post
Comment Guidelines
Trade With A Regulated Broker
Indices
Commodities
Bonds
Stocks
US 30
51,703.90
+472.2
+0.92%
US 500
7,816.30
+50.8
+0.65%
Dow Jones
51,654.95
+423.31
+0.83%
S&P 500
7,811.54
+46.18
+0.59%
Nasdaq
27,366.17
+172.83
+0.64%
S&P 500 VIX
14.84
-0.57
-3.70%
Dollar Index
102.03
+0.010
+0.01%
Crude Oil WTI Futures
91.66
+0.17
+0.19%
Brent Oil Futures
104.42
-0.30
-0.29%
Natural Gas Futures
3.20
+0.040
+1.14%
Gold Futures
4,220.30
+63.30
+1.52%
Silver Futures
61.11
+1.690
+2.84%
Copper Futures
6.71
+0.1400
+2.17%
US Soybeans Futures
1,292.25
+4.75
+0.37%
U.S. 10Y
5.244
+0.011
+0.21%
U.S. 30Y
5.599
-0.008
-0.14%
U.S. 5Y
5.021
+0.030
+0.60%
U.S. 3M
4.159
+0.008
+0.19%
US 10Y T-Note Futures
104.59
-0.13
-0.12%
Euro Bund Futures
121.08
+0.41
+0.34%
10-2 Yield Spread
31.32
+4.15
+15.27%
AAPL
336.64
-3.78
-1.11%
NVDA
229.28
-1.20
-0.52%
GOOGL
351.66
+3.37
+0.97%
TSLA
382.70
+7.70
+2.05%
AMZN
262.43
+8.37
+3.29%
NFLX
70.30
-1.27
-1.77%
META
718.67
-2.22
-0.31%
Advertisement
Most Popular Articles
News
Analysis
8 emerging markets to consider in 2027: HSBC
By Investing.co
...
Oct 11, 2026
Iran rejects U.S. stance on Hormuz as Trump weighs strikes over Riyadh attacks
By Investing.co
...
Oct 11, 2026
Will rising French bond spreads disrupt the rally in European stocks?
By Investing.co
...
Oct 10, 2026
Investors are likely to focus on SpaceX’s Starship tech milestones, not results
By Investing.co
...
Oct 12, 2026
Russia and Ukraine agree to energy ceasefire amid U.S. threat to cut military aid
By Investing.co
...
Oct 11, 2026
Beyond Chips: The 3 Layers of the AI Value Chain
By Ivana Delevs
...
Oct 10, 2026
OpenAI’s $20B Revenue Gap: Warning Signs for US Stocks?
By Lee Yang
Oct 09, 2026
Treasury Auctions Explained: Why Bond Auctions Matter Even If You Dont Trade Bonds
By Matthew Well
...
Oct 10, 2026
Sequence of Return Risk: The Math That Breaks Retirements
By Lance Robert
...
Oct 10, 2026
Gambling Epidemic: Gen Z Betting Against Their Future?
By Lance Robert
...
Oct 09, 2026
More News
Market Movers
Most Active
Gainers %
Losers %
Name
Last
Chg. %
Vol.
MU
1,029.00
-0.66%
19.92M
NVDA
229.28
-0.52%
84.65M
SPCX
162.57
+1.25%
93.04M
TSLA
382.70
+2.05%
38.95M
AAPL
336.64
-1.11%
37.88M
MSFT
535.07
+2.38%
18.50M
AMZN
262.43
+3.29%
34.77M
Name
Last
Chg. %
Vol.
CCI
79.64
+15.60%
14.39M
MRNA
225.00
+14.21%
28.95M
HUM
431.87
+11.56%
4.99M
AMT
182.24
+9.30%
8.51M
SBAC
182.49
+7.34%
2.36M
DDOG
293.26
+7.11%
3.71M
AKAM
106.95
+6.00%
5.80M
Name
Last
Chg. %
Vol.
TMUS
148.58
-13.27%
19.03M
T
22.18
-10.82%
150.53M
VZ
41.65
-10.14%
95.17M
HPQ
30.20
-6.91%
16.70M
FMC
8.35
-6.39%
5.19M
CHTR
103.38
-5.74%
5.11M
FICO
667.58
-5.63%
1.09M
Advertisement
Trending Stocks
Name
Last
Chg. %
Vol.
PLTR
209.05
+5.17%
37.62M
NVDA
229.28
-0.52%
84.65M
SPCX
162.57
+1.25%
93.04M
MRNA
225.00
+14.21%
28.95M
MU
1,029.00
-0.66%
19.92M
Show more
Advertisement
ProPicks AI
AI-powered
stock picks
with a proven track record to
beat the S&P 500
.
Tech Titans
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Top Value Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best of Buffett
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Energy Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Financial Fortresses
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Quality Compounders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Small-Cap Sprinters
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Healthcare Heroes
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Beat the S&P 500
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Dominate the Dow
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mid-Cap Movers
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mexican Stock Exchange Leaders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best Brazilian Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Italian Market Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Alpha Germany Select
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Comments
Post
Comment Guidelines
Tools
Calendars
Economic Calendar
Earnings Calendar
Holiday Calendar
US Economy
Fed Rate Monitor Tool
US Treasury Yield Curve
More Tools
Stock Screener
Currency Converter
Markets
Ask WarrenAI
Stocks Picked by AI
Watchlist
Alerts
Top Brokers
Breaking News
Tools
Install Our App
Scan QR code to install app
Follow us
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
540ba99ce0· 2026-10-12 05:07 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前